Overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram/copper-induced oxidative stress and ferroptosis in renal cell carcinoma.

Abstract

Renal cell carcinoma (RCC) is the most common type of kidney cancer, and it appears to be highly susceptible to ferroptosis. Disulfiram, an alcoholism drug, has been shown to have anticancer properties in various studies, including those on RCC. However, the mechanism of the anticancer effect of disulfiram/copper on RCC remains unclear. In this study, we investigated the impact of disulfiram/copper on RCC treatment using both RCC cells and mouse subcutaneous tumor models. Our findings demonstrate that disulfiram/copper treatment reduced the viability of RCC cells, inhibited their invasion and migration, and disrupted mitochondrial homeostasis, ultimately leading to oxidative stress and ferroptosis. Mechanistically, disulfiram/copper treatment prolonged the half-life of NRF2 and reduced its degradation, but had no effect on transcription, indicating that the disulfiram/copper-induced increase in NRF2 was not related to transcription. Furthermore, we observed that disulfiram/copper treatment reduced the expression of NPL4, a ubiquitin protein-proteasome system involved in NRF2 degradation, while overexpression of NPL4 reversed NRF2 levels and enhanced disulfiram/copper-induced oxidative stress and ferroptosis. These results suggest that overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram/copper-induced oxidative stress and ferroptosis in RCC. In addition, our in vivo experiments revealed that disulfiram/copper synergized with sorafenib to inhibit the growth of RCC cells and induce ferroptosis. In conclusion, our study sheds light on a possible mechanism for disulfiram/copper treatment in RCC and provides a potential synergistic strategy to overcome sorafenib resistance.

• Authors: Xinmiao Ni, Chenglin Ye, Xi Yu, Ye Zhang, Yanguang Hou, Qingyuan Zheng, Zhiyuan Chen, Lei Wang, Xiaodong Weng, Chuan Yang, Xiuheng Liu
• Journal: European journal of pharmacology (Eur J Pharmacol) Vol. 960 Pg. 176110 (Dec 05 2023) ISSN: 1879-0712 [Electronic] Netherlands
• PMID: 37838104 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 Elsevier B.V. All rights reserved.

Chemical References

• Disulfiram
• Sorafenib
• Copper
• NF-E2-Related Factor 2

Topics

• Mice
• Animals
• Carcinoma, Renal Cell (drug therapy)
• Disulfiram (pharmacology)
• Ferroptosis
• Sorafenib (pharmacology)
• Copper (pharmacology)
• NF-E2-Related Factor 2 (metabolism)
• Kidney Neoplasms (drug therapy)
• Oxidative Stress